DN
DNTH.US Dianthus Therapeutics Inc.
- Market cap
- USD 5.17B
- P/E
- -
- P/B
- 4.20x
- ROE
- -14.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DNTH.US undervalued?
Graham numberThe Graham number of Dianthus Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dianthus Therapeutics Inc. fundamental analysis
No fundamental analysis for Dianthus Therapeutics Inc. yet.
Dianthus Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production…
Full company profileDianthus Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dianthus Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M | 3.25M |
| Gross Profit | -6.00K | -376K | -875K | -1.84M | -1.98M | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M | 3.14M |
| Operating Income | -9.27M | -35.7M | -60.0M | -83.0M | -78.7M | -13.1M | -29.7M | -48.2M | -102M | -178M | -222M |
| EBITDA | -9.26M | -35.1M | -56.6M | -74.9M | -73.0M | -11.1M | -28.3M | -43.2M | -84.6M | -162M | -183M |
| Net Income | -9.43M | -35.5M | -57.5M | -76.8M | -74.9M | -13.1M | -28.5M | -43.6M | -85.0M | -162M | -184M |
| EPS | -4.27 | -16 | -28 | -33 | -27 | -3.82 | -7.60 | -8.45 | -2.55 | -4.30 | -3.20 |
| Balance Sheet | |||||||||||
| Total Assets | 11.3M | 54.5M | 157M | 162M | 162M | 190M | 83.1M | 179M | 374M | 531M | 1.28B |
| Total Liabilities | 2.30M | 4.14M | 11.7M | 20.3M | 17.7M | 17.3M | 9.45M | 10.5M | 21.5M | 37.5M | 34.8M |
| Shareholders' Equity | 9.04M | 50.3M | 146M | 141M | 144M | 173M | 73.7M | 169M | 352M | 493M | 1.24B |
| Cash & Short-term Investments | 4.54M | 51.6M | 143M | 146M | 149M | 177M | 75.5M | 174M | 275M | 404M | 838M |
| Total Debt | - | - | - | - | - | - | 788K | 585K | 1.49M | 1.39M | 1.21M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.53M | -22.3M | -41.9M | -57.1M | -64.0M | -59.5M | -29.1M | -36.9M | -78.2M | -129M | -171M |
| Capital Expenditure | 139K | 2.20M | 7.67M | 3.06M | 400K | 1.26M | 139K | 110K | 105K | 213K | 745K |
| Free Cash Flow | -6.67M | -24.5M | -49.6M | -60.2M | -64.4M | -60.8M | -29.2M | -37.0M | -78.3M | -129M | -172M |
| Ratios | |||||||||||
| ROE | -104.3% | -70.5% | -39.5% | -54.4% | -52.1% | -7.6% | -38.7% | -25.8% | -24.1% | -32.9% | -14.8% |
| ROA | -83.2% | -65.2% | -36.6% | -47.5% | -46.4% | -6.9% | -34.3% | -24.3% | -22.7% | -30.6% | -14.4% |
| Net Profit Margin | - | - | - | - | - | -888.1% | -443.8% | -1,541.2% | -1,362.8% | -7,973.3% | -5,657.0% |
| Debt to Equity | - | - | - | - | - | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dianthus Therapeutics Inc. dividends
Dianthus Therapeutics Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:16 on Sep 12, 2023.
Who owns Dianthus Therapeutics Inc.
- Insiders 0.12%
- Institutions 99.88%
- Public & others 0.00%
- Shares outstanding 56.3M
- Free float 56.2M
Top funds holding DNTH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.70M | 3.03% | +3.10% | Sep 2026 |
| Fidelity Growth Company Fund | 1.59M | 2.83% | 0.00% | Aug 2026 |
| Vanguard Health Care Inv | 1.50M | 2.67% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.48M | 2.63% | +2.68% | Oct 2026 |
| T. Rowe Price Capital Appreciation | 1.29M | 2.30% | -15.17% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 1.22M | 2.16% | -0.57% | Sep 2026 |
| iShares Russell 2000 ETF | 1.20M | 2.13% | 0.00% | Oct 2026 |
| Polar Capital Biotech S Inc | 965K | 1.71% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 730K | 1.30% | 0.00% | Sep 2026 |
| T. Rowe Price Instl Small-Cap Stock | 654K | 1.16% | -2.82% | Sep 2026 |
| Vanguard Small Cap Index | 597K | 1.06% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 569K | 1.01% | -11.03% | Sep 2026 |
| Fidelity Small Cap Index | 518K | 0.92% | +0.14% | Aug 2026 |
| T. Rowe Price Mid-Cap Growth | 514K | 0.91% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth | 468K | 0.83% | 0.00% | Aug 2026 |
| Franklin Biotechnology Discv A(acc)USD | 465K | 0.83% | 0.00% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 463K | 0.82% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 450K | 0.80% | +33.63% | Aug 2026 |
| Fidelity Growth Company K6 | 445K | 0.79% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 444K | 0.79% | -0.38% | Oct 2026 |
Top institutions holding DNTH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 8.20M | 14.57% | +5.56% | Jun 2026 |
| BlackRock Inc | 4.12M | 7.33% | +29.86% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 3.89M | 6.91% | +200.92% | Jun 2026 |
| Wellington Management Company LLP | 3.23M | 5.74% | +24.43% | Jun 2026 |
| Fairmount Funds Management LLC | 2.54M | 4.51% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.51M | 4.47% | +119.27% | Jun 2026 |
| State Street Corp | 2.36M | 4.19% | +68.52% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.16M | 3.84% | +6.32% | Jun 2026 |
| Avidity Partners Management LP | 2.10M | 3.74% | -50.00% | Jun 2026 |
| Octagon Capital Advisors LP | 1.84M | 3.27% | -5.39% | Jun 2026 |
| TCG Crossover Management, LLC | 1.68M | 2.98% | 0.00% | Jun 2026 |
| Fred Alger Management, LLC | 1.30M | 2.31% | +12.10% | Jun 2026 |
| Geode Capital Management, LLC | 1.26M | 2.24% | +37.36% | Jun 2026 |
| VR Adviser, LLC | 1.18M | 2.10% | 0.00% | Jun 2026 |
| UBS Group AG | 1.14M | 2.03% | +45.95% | Jun 2026 |
| Deerfield Management Co | 1.13M | 2.00% | +10.35% | Jun 2026 |
| Jennison Associates LLC | 1.02M | 1.82% | +110.61% | Jun 2026 |
| Polar Capital Holdings PLC | 1.02M | 1.81% | -5.32% | Jun 2026 |
| Citadel Advisors Llc | 975K | 1.73% | -39.46% | Jun 2026 |
| Franklin Templeton Inc | 969K | 1.72% | +0.08% | Jun 2026 |
Dianthus Therapeutics Inc. company profile
- Company name
- Dianthus Therapeutics Inc.
- Ticker
- DNTH.US
- Exchange
- USA Stocks
- Listed since
- Sep 12, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Fiscal year end
- December
- Address
- 7 Times Square, New York, NY, United States, 10036
- Phone
- 929 999 4055
- Website
- dianthustx.com
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics Inc. management
10- Mr. Marino Garcia M.B.A.President, CEO & Director · born 1966
- Mr. Ryan SavitzExecutive VP, CFO, Chief Business Officer & Treasurer · born 1989
- Dr. Simrat Randhawa M.B.A., M.D.Executive VP and Head of R&D · born 1970
- Mr. Edward G. CarrSenior VP & Chief Accounting Officer · born 1969
- Mr. Judson TaylorSenior VP & Head of Technical Operations
- Ms. Jennifer Davis RuffVP and Head of Investor Relations & Corporate Affairs
- Mr. Adam M. Veness Esq.Senior VP, General Counsel & Secretary · born 1986
- Ms. Kristina MaximenkoChief People Officer
- Ms. Rashieda GluckHead of Clinical Development Operations
- Mr. Scott Nogi M.B.A.Head of Business Operations